Table 1.
Patient characteristics, mean (SD) | Cohort 1, n = 35 | Cohort 3, n = 152 | ||
---|---|---|---|---|
Age, y | 52.7 (13.8) | 51.1 (13.6) | ||
Education level, y | 14.7 (1.90) | 14.7 (2.3) | ||
Time since diagnosis, mo | 70.8 (64.8) | 72.5 (56.4) | ||
Patient characteristics, no. (%) | ||||
Sex | ||||
Men | 16 (46) | 71 (47) | ||
Women | 19 (54) | 81 (53) | ||
Race and ethnicity | ||||
Hispanic, black non-Hispanic, Asian, and Native American | 6 (17) | 37 (24) | ||
White non-Hispanic | 29 (83) | 115 (76) | ||
Marital status | ||||
Married | 27 (77) | 115 (76) | ||
Not married | 8 (23) | 37 (24) | ||
Employment status | ||||
Employed outside the home | 20 (57) | 91 (60) | ||
Not employed | 15 (43) | 61 (40) | ||
ECOG PS score | ||||
Good (1 or lower) | 34 (97) | 149 (98) | ||
Poor (2 or higher) | 1 (3) | 3 (2) | ||
CML phase | ||||
Chronic phase | 32 (91) | 148 (97) | ||
Accelerated phase | 1 (3) | 1 (1) | ||
Blast crisis | 2 (6) | 3 (2) | ||
Disease response | ||||
Hematologic | 34 (97) | 131 (86) | ||
Complete cytogenetic | 26 (74) | 131 (86) | ||
Complete or major molecular | 60 (21) | 53 (80) | ||
Previous therapy | ||||
Yes | 28 (80) | 116 (76) | ||
No | 7 (20) | 36 (24) | ||
Treatment | Previous | Current | Previous | Current |
Imatinib | 23 (66) | 7 (20) | 57 (38) | 71 (47) |
Dasatinib | 6 (17) | 16 (46) | 13 (9) | 34 (22) |
Nilotinib | 4 (11) | 4 (11) | 9 (6) | 22 (14) |
Bosutinib | 5 (14) | 1 (3) | 4 (3) | 6 (4) |
Ponatinib | 0 | 3 (8) | 0 | 5 (3) |
Bafetinib | 1 (3) | 1 (3) | 0 | 1 (1) |
Rebastinib | 0 | 1 (3) | 0 | 3 (2) |
Other drug therapy | 22 (63) | 1 (3) | 88 (58) | 3 (2) |
HSCT in last 3 mo | 5 (14) | 0 (0) | 7 (5) | 1 (1) |
No treatment | 0 | 1 (3) | 0 | 7 (5) |
HSCT, hematopoietic stem cell transplant.